The collaboration integrates AI-driven blood testing with a nationwide hepatology specialist network to reduce diagnostic delays.
Helio Genomics has partnered with LiverRight, a virtual clinic for liver disease in adults, to combine the company’s LiverTrace blood-based liver cancer test with LiverRight’s network of hepatology specialists across all 50 states.
The partnership aims to address gaps in liver disease diagnosis and specialist access. Liver disease affects approximately 1 in 3 US adults, with metabolic dysfunction-associated steatotic liver disease (MASLD) alone impacting roughly 30% of the adult population, according to a release from Helio Genomics. MASLD is the leading cause of cirrhosis and liver cancer for women in the United States and the second leading cause for men, yet patients often face months-long delays to see a specialist.
“This partnership represents a new standard in hepatocellular carcinoma care,” says Dr Bharat Tewarie, chief executive officer of Helio Genomics, in a release. “When it comes to liver cancer, every week matters—delays in diagnosis can be the difference between a curable condition and a life-threatening battle.”
AI-Powered Blood Testing Integration
LiverTrace uses artificial intelligence and machine learning to detect cancer biomarkers through a simple blood draw, identifying potential liver cancer even before a tumor is visible through ultrasound. Patients who receive their LiverTrace results can immediately connect with LiverRight’s board-certified hepatologists and hepatology Advanced Practice Providers for expert interpretation and advancement into formal diagnosis and treatment when relevant.
The test is designed for adults at risk for liver cancer, including those with family history, previous liver issues, or lifestyle factors that increase risk. After ordering, a collection kit is shipped to the patient’s home, and a mobile phlebotomist visits at the patient’s convenience for professional blood draw. Results are available within 14 business days through a secure online portal.
“Liver cancer identification has historically started with the patient moving to imaging, specifically a liver MRI,” says Brandon Tudor, CEO of LiverRight, in a release. “There has never been an essential noninvasive and convenient intervention as a potential on-ramp to imaging, until LiverTrace.”
Clinical Impact of Early Detection
The timing of liver cancer diagnosis significantly affects patient outcomes. When caught early, before the liver tumor is large or has spread, several potentially curative options are available, including liver transplantation.
“With early-stage diagnosis, five-year survival rates can exceed 70%, sometimes higher depending on the treatment modality,” says Dr Alexander Lalos, chief medical officer of LiverRight, in a release. “In advanced stages, survival drops to mere months or a few years, even with treatment. Early detection can triple survival chances.”
LiverRight’s mission centers on reducing time to diagnosis and time to treatment initiation for all forms of liver disease. The clinic provides same-week access to board-certified hepatologists and hepatology Advanced Practice Providers who diagnose and treat all forms of liver disease, from MASLD and viral hepatitis to cirrhosis and liver cancer.
Helio Genomics is a commercial-stage, AI-driven techbio company specializing in diagnostics technology for cancer detection. The company’s blood-based multi-analyte platform uses machine learning and deep learning to detect cancer biomarkers. The technology has been clinically validated in studies with thousands of patients.
ID 397067727 © Chormail | Dreamstime.com
